Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

21
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
21
Inflammation01:38

Inflammation

54.2K
Overview
54.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

19
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
19
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

13
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
13
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

39
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
39

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CSF1R regulates monocyte subset differentiation and intracellular metabolism.

Nature communications·2026
Same author

Editorial: Cardiovascular calcification: disease mechanisms, clinical phenotypes and therapeutic strategies.

Frontiers in cardiovascular medicine·2026
Same author

Adipose-Tissue Macrophage Diversity and Functions.

International journal of molecular sciences·2026
Same author

Physiological mechanisms underlying enhanced performance with blood flow restriction training: neuromuscular, vascular and metabolic adaptations.

The Journal of physiology·2025
Same author

Correction: The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.

Trials·2025
Same author

The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.

Trials·2025

Related Experiment Video

Updated: Aug 5, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Atherosclerosis Calcification: Focus on Lipoproteins.

Jaap G Neels1, Georges Leftheriotis2, Giulia Chinetti3

  • 1Université Côte d'Azur, INSERM, C3M, 06200 Nice, France.

Metabolites
|March 29, 2023
PubMed
Summary

Lipoproteins and their proteins significantly impact vascular calcification (VC). Understanding these roles is key to developing new treatments for this cardiovascular disease.

Keywords:
calciumcardiovascular diseasecholesterolinflammationlipidsvascular calcification

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.9K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.6K

Related Experiment Videos

Last Updated: Aug 5, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.9K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.6K

Area of Science:

  • Cardiovascular Science
  • Biochemistry
  • Pathology

Background:

  • Atherosclerosis involves lipid accumulation and vascular calcification (VC).
  • Lipoproteins are central to atherosclerosis and VC development.
  • Specific lipoproteins like LDL, VLDL, and Lp(a) stimulate VC, while HDL reduces it.

Purpose of the Study:

  • To elucidate the mechanisms of lipoprotein and apolipoprotein involvement in vascular calcification.
  • To identify key molecular players in VC pathogenesis for therapeutic targeting.

Main Methods:

  • Review of existing literature on lipoproteins, apolipoproteins, and vascular calcification.
  • Analysis of the roles of specific lipoprotein classes (LDL, VLDL, HDL) and apolipoproteins (apoAI, apoB, apoCIII).
  • Examination of lipoprotein metabolism, oxidation, and enzymatic modifications (ATX, PCSK9) in VC.

Main Results:

  • Apolipoprotein AI (apoAI) exhibits anti-calcific properties.
  • Apolipoprotein B (apoB) and apolipoprotein CIII (apoCIII) promote VC.
  • Oxidized LDL (OxLDL) is more pro-calcific than native LDL, and oxidized HDL can become pro-calcific.
  • Enzymes like autotaxin (ATX) and PCSK9 stimulate VC.

Conclusions:

  • Lipoprotein composition, metabolism, and modification critically influence vascular calcification.
  • Targeting specific lipoproteins and apolipoproteins offers potential therapeutic strategies for VC.
  • Further understanding of these mechanisms is essential for preventing and treating VC and associated cardiovascular diseases.